As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.
At Karyopharm Therapeutics ( KPTI ), a filing with the SEC revealed that on Thursday, Director Barry E. Greene purchased 3,000 shares of KPTI, at a cost of $29.31 each, for a total investment of $87,938. Greene was up about 13.5% on the buy at the high point of today's trading session, with KPTI trading as high as $33.28 at last check today. Karyopharm Therapeutics is trading up about 10.9% on the day Tuesday. This buy marks the first one filed by Greene in the past year.
And also on Thursday, Chief Executive Officer Michelle Dipp bought $32,490 worth of OvaScience ( OVAS ), buying 1,000 shares at a cost of $32.49 each. Before this latest buy, Dipp purchased OVAS at 4 other times during the past year, for a total cost of $18,614 at an average of $11.28 per share. OvaScience is trading up about 2.9% on the day Tuesday. Dipp was up about 8.3% on the purchase at the high point of today's trading session, with OVAS trading as high as $35.20 in trading on Tuesday.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.